Vascular Neurology Research


Expertise:

The UT Vascular Neurology division is a leader in stroke research that includes funded trials from private industry, state of Texas Lone Star Stroke Consortium, and federal NIH StrokeNet. Our comprehensive stroke research focuses on acute stroke treatment with Tenecteplase, secondary stroke prevention with antithrombotics and statins, as well as rehabilitation and recovery for determinants of functional and cognitive outcomes. The research team includes a dedicated stroke research nurse, regulatory affairs analyst, and neuroscience research operations director.

  • ASPIRE

     Principal Investigator:
    Reza Behrouz, DO

     

     

    https://clinicaltrials.gov/study/NCT03907046

    Type of Study:
    International/Randomized Control

    Summary
    ASPIRE is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and non-valvular AF. Seven hundred patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months. The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause. The secondary efficacy outcome is the change in the modified Rankin Scale score. Recruitment will take place at sites coordinated through the NIH/NINDS StrokeNet.

    Link to Sponsor’s Website:
    https://www.nihstrokenet.org/trials/aspire-trial/home

    Study Coordinator:
    Jody Richardson
    Office: 210-450-0533
    Email: richardsonj1@uthscsa.edu

     

     

    Study Coordinator:
    Tonya Randolph
    Office: 210-450-8460
    Email: randolpht@uthscsa.edu

  • CAPTIVA

    Principal Investigator:
    Sujani Bandela, MD

     

     

    https://clinicaltrials.gov/study/NCT05047172

    Type of Study:
    International/Randomized Control

    Summary
    The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death. This study is relevant to public health because narrowing of brain arteries is one of the most common causes of stroke worldwide. Compelling evidence suggests novel antithrombotic medications could reduce the rate of stroke in patients with narrowed brain arteries. The proposed study will directly compare novel antithrombotic medications to standard care antiplatelet medications for preventing stroke and death from vascular causes in patients with narrowed brain arteries.

    Link to Sponsor’s Website:
    https://nihstrokenet.org/trials/captiva/home

    Study Coordinator:
    Jody Richardson
    Office: 210-450-0533
    Email: richardsonj1@uthscsa.edu

     

     

    Study Coordinator:
    Tonya Randolph
    Office: 210-450-8460
    Email: randolpht@uthscsa.edu

  • DISCOVERY

    Principal Investigator:
    Andrew Slusher, MD

     

     

    https://clinicaltrials.gov/study/NCT04916210

     

    Type of Study: Observational

    Summary

    The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a “stroke” is defined as either (1) an acute ischemic stroke (AIS, or blood clot in the brain), (2) an intracerebral hemorrhage (ICH, or bleeding in the brain), (3) or an aneurysmal subarachnoid hemorrhage (aSAH, or bleeding around the brain caused by an abnormal bulge in a blood vessel that bursts)

     

    Link to Sponsor’s Website:
    https://discoverystudy.org/study-overview

    Study Coordinator:
    Jody Richardson
    Office: 210-450-0533
    Email: richardsonj1@uthscsa.edu

     

     

    Study Coordinator:
    Tonya Randolph
    Office: 210-450-8460
    Email: randolpht@uthscsa.edu

  • REvive

     Principal Investigator:
    Reza Behrouz, DO

     

     

    https://clinicaltrials.gov/study/NCT05953480

    Type of Study:
    International/Randomized Control

    Summary
    The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS).

     

    Study Coordinator:
    Jody Richardson
    Office: 210-450-0533
    Email: richardsonj1@uthscsa.edu

     

     

    Study Coordinator:
    Tonya Randolph
    Office: 210-450-8460
    Email: randolpht@uthscsa.edu

  • SATURN

    Principal Investigator:
    Lee Birnbaum, MD

     

     

    https://clinicaltrials.gov/study/NCT03936361

     

    Type of Study: Interventional/Randomized Control

    Summary

    The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual’s Apolipoprotein-E (APOE) genotype.

    An MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cerebral small vessel disease, and whether the presence/burden of hemorrhagic markers (i.e. cerebral microbleeds and/or cortical superficial siderosis) on baseline MRI influences the risk of ICH recurrence on/off statin therapy

     

    Link to Sponsor’s Website:
    https://www.nihstrokenet.org/trials/saturn-trial/home

    Study Coordinator:
    Jody Richardson
    Office: 210-450-0533
    Email: richardsonj1@uthscsa.edu

     

     

    Study Coordinator:
    Tonya Randolph
    Office: 210-450-8460
    Email: randolpht@uthscsa.edu